{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:15Z","timestamp":1791994575237,"version":"4.4.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ofatumumab, a fully human anti-CD20 monoclonal antibody administered subcutaneously and indicated for multiple sclerosis, might theoretically be effective for patients with pemphigus vulgaris (PV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of ofatumumab in patients with PV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cohort study was based on a registry database of autoimmune bullous diseases at West China Hospital (AIBD-WCH), including two groups. One was ofatumumab (OFA) group, involving patients receiving ofatumumab subcutaneous injections (2\u00d720mg, 2 weeks apart) and systemic glucocorticoids with\/without immunosuppressant. The glucocorticoids control (GC) group was matched using propensity score matching in a 1:2 ratio based on sex, age and body mass index. Both groups completed regular follow-up for 52 weeks. The primary endpoint was the proportion of patients achieving complete remission during therapy (CRDT) at week 52. Secondary endpoints included maintaining treatment (MT) with daily prednisone doses &amp;lt;0.2 mg\/kg\/d, relapse rate, the change of pemphigus disease area index and cumulative glucocorticoid doses. Safety results were also collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen and thirty-two patients were included in OFA and GC groups, respectively. At week 52, more patients in OFA group achieved CRDT (31.2% versus 3.12%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.012) and MT (68.8% versus 25.0%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.009). Furthermore, patients in OFA group took lower cumulative glucocorticoid doses by week 52 (6186 [SD: 1177]mg versus 9317 [SD: 1579]mg,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001). A patient in OFA group experienced gastric hemorrhage, which was judged to be unrelated to ofatumumab, while two in GC group developed lung infections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ofatumumab combined with glucocorticoids demonstrated favorable effectiveness compared with GC group, without increasing severe adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1537334","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:26:07Z","timestamp":1753421167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeongah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2302071","DOI":"10.1080\/09546634.2024.2302071","article-title":"The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study","author":"Zhou","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1187","article-title":"Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","article-title":"A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab","volume":"79","author":"Saleh","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16561","article-title":"Long-term outcomes of rituximab therapy in pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: A phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17108","article-title":"Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab","volume":"51","author":"Zhang","year":"2024","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.05.034","article-title":"Refractory pemphigus vulgaris successfully treated with ofatumumab","volume":"6","author":"Klufas","year":"2020","journal-title":"JAAD Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20245","article-title":"Evaluation of combination therapy with ofatumumab and systemic corticosteroids for pemphigus: A multi-centre cohort study","volume":"39","author":"Mao","year":"2024","journal-title":"Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12486","article-title":"Japanese guidelines for the management of pemphigus","volume":"41","author":"Amagai","year":"2014","journal-title":"J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the ritux 3 trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15397","article-title":"Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients","volume":"35","author":"Nosrati","year":"2022","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: A post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy: Immunological parameters in patients with PV treated with rituximab and IVIG","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40263-021-00895-w","article-title":"Population pharmacokinetic\u2013B cell modeling for ofatumumab in patients with relapsing multiple sclerosis","volume":"36","author":"Yu","year":"2022","journal-title":"CNS Drugs"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti\u2013desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849790","article-title":"The diversity of serum anti-DSG3 IgG subclasses has a major impact on pemphigus activity and is predictive of relapses after treatment with rituximab","volume":"13","author":"Golinski","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T05:26:08Z","timestamp":1753421168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1537334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1537334"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1537334","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"1537334"}}